TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2812837

Group type: EXPERIMENTAL
Intervention: Clomipramine (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Maprotiline (n = 18)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Historical control subjects (n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patients with psychogenic pain with affective symptoms (n = 62)
Number of subjects: 43
Study: 1120837

Group type: EXPERIMENTAL
Intervention: Behavioral counseling group with hierarchically organized role playing and correctional feedback exercises
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Counseling plus group desensitization
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Microlab emphasizing structured real life interactions with females
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo procedure designed to increase personal awareness of nondating factors
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 84
Study: 31233373

Group type: EXPERIMENTAL
Intervention: Compression therapy using a sports bra of compression type for 9 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard bra for 9 months (Control)
Number of subjects: 56
Study: 28837504

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 7036

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 7036

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7036

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7036
Study: 25319385

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 997

Group type: COMPARATOR
Intervention: Crystalloids
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Presepsin concentration
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Presepsin concentration changes from day 1 to day 2
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Inappropriate antibiotic therapy
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic therapy
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Negative blood cultures
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Positive blood cultures
Number of subjects: 997
Study: 22407393

Group type: EXPERIMENTAL
Intervention: Pascal dynamic contour tonometry
Number of subjects: 97

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 97
Study: 21323394

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100-200 mg/day)
Number of subjects: 123
Study: 19165196

Group type: EXPERIMENTAL
Intervention: Xelox+cetuximab
Number of subjects: 804

Group type: COMPARATOR
Intervention: Xelox
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: OxMdG+cetuximab
Number of subjects: 804

Group type: COMPARATOR
Intervention: OxMdG
Number of subjects: 804
Study: 17465457

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of EUS and MMP-9
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Serum MMP-9 levels
Number of subjects: 63
Study: 15163163

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy Scale‐General (FACT‐G)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 968

Group type: COMPARATOR
Intervention: Breast cancer survivors
Number of subjects: 968

Group type: COMPARATOR
Intervention: Survivors of Hodgkin's disease
Number of subjects: 968
Study: 11310450

Group type: EXPERIMENTAL
Intervention: Treatment for secondary NHL
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for all patients with secondary NHL
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Freedom from treatment failure (FFTF) for all patients with secondary NHL
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for patients with diffuse large-cell lymphoma
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Freedom from treatment failure (FFTF) for patients with diffuse large-cell lymphoma
Number of subjects: 52
Study: 9146102

Group type: EXPERIMENTAL
Intervention: Nature and severity of the plaintiff's injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injury severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability and mental suffering associated with injuries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived fault
Number of subjects: 0
Study: 8198080

Group type: EXPERIMENTAL
Intervention: FR‐3 appliance therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 31124042

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2.5 mg or 100,000 IU)
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study: 27259508

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical therapy (CMT)
Number of subjects: 100
Study: 25564317

Group type: EXPERIMENTAL
Intervention: Standardized protocol for early stages of Convulsive Status Epilepticus (CSE) management
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Specific guidelines for Convulsive Refractory Status Epilepticus (CRSE) management
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Involvement of neurologists in management
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Access to continuous EEG monitoring
Number of subjects: 55
Study: 23415417

Group type: EXPERIMENTAL
Intervention: Potentially harmful supplement use
Number of subjects: 21169

Group type: COMPARATOR
Intervention: No CKD
Number of subjects: 21169

Group type: COMPARATOR
Intervention: At risk of CKD
Number of subjects: 21169

Group type: COMPARATOR
Intervention: Stages 1/2 CKD
Number of subjects: 21169

Group type: COMPARATOR
Intervention: Stages 3/4 CKD
Number of subjects: 21169
Study: 20637899

Group type: EXPERIMENTAL
Intervention: Interruptive alerts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 0
Study: 18484428

Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16939998

Group type: EXPERIMENTAL
Intervention: Theophylline treatment in obese participants
Number of subjects: 488

Group type: COMPARATOR
Intervention: Theophylline treatment in non-obese participants
Number of subjects: 488
Study: 14671905

Group type: EXPERIMENTAL
Intervention: Surface low-level endobronchial narcosis by isoflurane with high epidural anesthesia by bupivakain and fentanyl
Number of subjects: 82

Group type: COMPARATOR
Intervention: Isoflurane and intravenous bolus injections of fentanyl with epidural anesthesia by morphine at lumbar level
Number of subjects: 82
Study: 10735887

Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg/d
Number of subjects: 769

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 40 mg four times daily
Number of subjects: 769
Study: 9367070

Group type: EXPERIMENTAL
Intervention: Oral retinol (25,000 units)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Isotretinoin (5-10 mg)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study: 1396624

Group type: EXPERIMENTAL
Intervention: midazolam-flumazenil
Number of subjects: 80

Group type: COMPARATOR
Intervention: propofol
Number of subjects: 80
Study: 3891264

Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 77

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 77
Study: 31584684

Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for MRSA bacteremia
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for MRSA bacteremia
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for CAUTI
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for CAUTI
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for CLABSI
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for CLABSI
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for CDI
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for CDI
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intervention group for MRSA acquisition
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intervention group for VRE acquisition
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group for MRSA acquisition
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group for VRE acquisition
Number of subjects: 73
Study: 29972861

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: No fentanyl
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl and No fentanyl
Number of subjects: 212
Study: 27428192

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 134
Study: 25416557

Group type: EXPERIMENTAL
Intervention: Six sessions of basic counseling over a period of 3 to 4 months provided by trained community health workers (CHWs)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Three monthly phone calls from a CHW trained to conduct phone calls but not basic counseling
Number of subjects: 420
Study: 22136660

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) administered to mothers during late pregnancy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 20653331

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2148

Group type: EXPERIMENTAL
Intervention: β-blockers (titrated to heart rate)
Number of subjects: 2148
Study: 17355936

Group type: EXPERIMENTAL
Intervention: L-arginine (L-Arg) therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 68
Study: 15705120

Group type: EXPERIMENTAL
Intervention: venlafaxine XR 150 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: venlafaxine XR 75 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 12011124

Group type: COMPARATOR
Intervention: ACVBP chemotherapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem-cell transplantation (ASCT)
Number of subjects: 370

Group type: COMPARATOR
Intervention: ACVBP chemotherapy
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 370
Study: 9623011

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7672654

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, administered pre-operatively for three months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 28
Study: 2240053

Group type: EXPERIMENTAL
Intervention: Intranasal lysine vasopressin (LV)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 269932

Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aspirin, 650 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 200 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 37
Study: 31608821

Group type: EXPERIMENTAL
Intervention: Thin ideal images (for females)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Muscular ideal images (for males)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (images of houses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Psychological distress (K10 scale)
Number of subjects: 200
Study: 31553834

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg infusion on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg infusion)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Adalimumab (40 mg subcutaneous injection at week 1, 80 mg at week 2, and 40 mg every 2 weeks thereafter)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Adalimumab (40 mg subcutaneous injection)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 769

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 769
Study: 28915826

Group type: EXPERIMENTAL
Intervention: HuoXueSanFeng acupuncture combined with one antihypertensive medication
Number of subjects: 480

Group type: COMPARATOR
Intervention: One antihypertensive medication and basic treatments for ischemic stroke
Number of subjects: 480
Study: 26086941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200,000 IU cholecalciferol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400,000 IU cholecalciferol
Number of subjects: 30
Study: 24633278

Group type: EXPERIMENTAL
Intervention: Clear nail polish
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Red nail polish
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acrylic nails
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Black nail polish
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brown nail polish
Number of subjects: 50
Study: 21880326

Group type: EXPERIMENTAL
Intervention: Voice-therapy (direct treatment)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vocal-hygiene program (indirect treatment)
Number of subjects: 42
Study: 19744323

Group type: EXPERIMENTAL
Intervention: Bedside chair and bed pressure sensors with radio-paging alerting mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (without the use of sensors)
Number of subjects: 0
Study: 17902520

Group type: EXPERIMENTAL
Intervention: Excision with midline closure (EMC group)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Excision without closure (EWC group)
Number of subjects: 380
Study: 14630836

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with reaming
Number of subjects: 224

Group type: COMPARATOR
Intervention: Intramedullary nailing without reaming
Number of subjects: 224
Study: 11141029

Group type: EXPERIMENTAL
Intervention: Presurgical infant orthopedic treatment (PIO) during the first year of life
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nontreatment group (no PIO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Children with cleft lip and palate
Number of subjects: 20
Study: 9350557

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and toothpaste slurry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothpaste slurry and water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 0
Study: 8459971

Group type: EXPERIMENTAL
Intervention: Sodium etidronate 400 mg/day for 14 days followed by calcium carbonate 500 mg/day for 42 days plus norethindrone 2.5 mg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Norethindrone 10 mg/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: GnRH agonist only (Group III)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated controls (Group IV)
Number of subjects: 11
Study: 3533677

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg each morning for one day before reaching 3000m
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control groups (Caucasian subjects and lowland and highland Africans)
Number of subjects: 48
Study: 30873549

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30225268

Group type: EXPERIMENTAL
Intervention: Usual care plus a nurse‐led diabetes self‐management education for 12 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 142
Study: 26795100

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (HD)
Number of subjects: 0
Study: 24584065

Group type: EXPERIMENTAL
Intervention: Recording patient's estimated 3-month functional prognosis
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Patient wanted life support regardless of functional outcome
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (patient did not want continued life support without a reasonable chance of independent living)
Number of subjects: 630
Study: 22538118

Group type: EXPERIMENTAL
Intervention: Ginger (2 g ginger powder in hot water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no ginger)
Number of subjects: 10
Study: 19539141

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stenting (SES)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB) surgery
Number of subjects: 130
Study: 17611204

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control (no preimplantation genetic screening)
Number of subjects: 408
Study: 14993866

Group type: EXPERIMENTAL
Intervention: Lean beef
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lean poultry and fish
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 12638335

Group type: EXPERIMENTAL
Intervention: Progressive workload training (Group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Not trained (Group B)
Number of subjects: 16
Study: 10453796

Group type: EXPERIMENTAL
Intervention: Active bupropion
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Open-label bupropion
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Relapse-prevention phase (bupropion)
Number of subjects: 457
Study: 7775988

Group type: EXPERIMENTAL
Intervention: Research-related activities
Number of subjects: 4920

Group type: EXPERIMENTAL
Intervention: Patient care activities
Number of subjects: 4920

Group type: EXPERIMENTAL
Intervention: Personal time
Number of subjects: 4920

Group type: EXPERIMENTAL
Intervention: Time spent in transit
Number of subjects: 4920
Study: 2104627

Group type: EXPERIMENTAL
Intervention: Angiotensin-II infusion
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Angiotensin-III infusion
Number of subjects: 83

Group type: COMPARATOR
Intervention: Captopril (ACE inhibitor)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor) for 30 days
Number of subjects: 83
Study: 211983

Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate high-dose (1 ml) with family therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fluphenazine enanthate low-dose (0.25 ml) with no therapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate low-dose (0.25 ml) with family therapy
Number of subjects: 104
Study: 31277886

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training program in 10 sessions for 45 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (did not participate in the cognitive rehabilitation program)
Number of subjects: 24
Study: 28797624

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 26071592

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 75
Study: 23343682

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 21107542

Group type: EXPERIMENTAL
Intervention: High-altitude residents
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sea level residents
Number of subjects: 28
Study: 19223643

Group type: EXPERIMENTAL
Intervention: IDX899 50 mg capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDX899 200 mg capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDX899 800 mg once daily (QD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDX899 400 mg twice daily (BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDX899 under fed conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17357181

Group type: EXPERIMENTAL
Intervention: 12-week controlled antidepressant monotherapy trial
Number of subjects: 42
Study: 16036027

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release metoprolol
Number of subjects: 0
Study: 11345160

Group type: EXPERIMENTAL
Intervention: Active dilator (Breathe Right, 3M)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active dilator (Breathe Right, 3M) in subgroup of habitual snorers (n = 6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 18
Study: 9325593

Group type: EXPERIMENTAL
Intervention: Subjects who were outperformed by a confederate on a perceptual intelligence test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects who outperformed confederates on a perceptual intelligence test
Number of subjects: 0
Study: 7950110

Group type: EXPERIMENTAL
Intervention: Clear corneal tunneling
Number of subjects: 54

Group type: COMPARATOR
Intervention: Corneoscleral tunneling (Control)
Number of subjects: 54
Study: 6476557

Group type: EXPERIMENTAL
Intervention: New cardiopulmonary-cerebral resuscitation therapies
Number of subjects: 0
Study: 31409338

Group type: EXPERIMENTAL
Intervention: CDSS generating alerts based on clinically relevant pDDIs
Number of subjects: 9
Study: 29265923

Group type: EXPERIMENTAL
Intervention: Functionally matched D‐PSAs
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Mismatched D‐PSAs (particularly refutational)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Moderately matched messages
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: One‐sided moderately matched messages
Number of subjects: 567

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 567
Study: 27938637

Group type: EXPERIMENTAL
Intervention: Peer education program delivered by peer educators
Number of subjects: 0